Takeda, Ascentage Pharma sign option agreement for olverembatinib
This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the
UK-based Yellowstone Biosciences has announced its launch with a £16.5m investment from Syncona to develop soluble bispecific T-cell receptor (TCR)-based therapies.
These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation